發(fā)布時(shí)間：2018-02-26 23:15

  本文關(guān)鍵詞： 血友病 預(yù)防性治療 多維度決策分析方法　出處：《中國衛(wèi)生經(jīng)濟(jì)》2017年09期 　論文類型：期刊論文

【摘要】：目的:比較影響血友病A治療的主要療效因素,評價(jià)不同治療方案的優(yōu)缺點(diǎn),進(jìn)而為治療方案的決策提供參考。方法:采用多維度決策分析方法 (MDCA),通過組織專家組會議,對反映血友病治療效果的10個(gè)特性因素及其標(biāo)準(zhǔn)劑量的預(yù)防治療、中低劑量預(yù)防治療和按需治療這三種治療方案進(jìn)行評分;并獲得不同特性指標(biāo)的權(quán)重。結(jié)果:普遍認(rèn)為標(biāo)準(zhǔn)預(yù)防治療方案最好;對費(fèi)用分析后發(fā)現(xiàn),標(biāo)準(zhǔn)劑量的預(yù)防治療費(fèi)用高(34.5萬元),但治療效果遠(yuǎn)好于中低劑量預(yù)防治療和按需治療方案。結(jié)論:從長期的成本效果分析來看,預(yù)防性治療可以減少并發(fā)癥的發(fā)生,并且降低終生的醫(yī)療成本。但目前我國各地對血凝8因子醫(yī)保報(bào)銷政策不同,而且補(bǔ)償水平不一,急需進(jìn)一步提高。
[Abstract]:Objective: to compare the main factors affecting the therapeutic effect of hemophilia A, evaluate the advantages and disadvantages of different treatment schemes, and provide reference for the decision of treatment regimen. Methods: the expert group meeting was organized by using the method of multi-dimensional decision analysis (MDCAA). Ten characteristic factors and their standard dose prophylaxis therapy, middle and low dose prophylaxis therapy and on-demand treatment were evaluated. The weight of different characteristic indicators was obtained. Results: standard prophylaxis was generally considered to be the best; cost analysis showed that, The cost of standard dose prophylaxis is high (345,000 yuan), but the therapeutic effect is much better than that of low-dose preventive therapy and on-demand treatment. Conclusion: from the long-term cost-effect analysis, prophylactic treatment can reduce the incidence of complications. But at present, the reimbursement policy of hemagglutination 8 factor medical insurance is different in our country, and the compensation level is different, so it needs to be further improved.
【作者單位】： 復(fù)旦大學(xué)公共衛(wèi)生學(xué)院;上海市醫(yī)學(xué)科學(xué)技術(shù)情報(bào)研究所(上海市衛(wèi)生發(fā)展研究中心)衛(wèi)生政策研究部;
【分類號】：R554.1

【相似文獻(xiàn)】

相關(guān)重要報(bào)紙文章 前1條

1 本報(bào)記者 田雅婷;“玻璃人”更需要預(yù)防性治療[N];光明日報(bào);2013年

，

本文編號：1540101